Date: 2016-05-09
Type of information: Financing round
Company: AC Immune (Switzerland)
Investors: undisclosed institutions and existing shareholders
Amount: CHF 42.7 million (€ 38.64 million)
Funding type: series E financing round
Planned used: The proceeds of the financing, together with existing cash resources, will be used by AC Immune to advance its clinical and pre-clinical therapeutic and diagnostic product pipeline in Alzheimer’s disease and other neurodegenerative diseases. AC Immune’s two proprietary technology platforms create antibodies, small molecules and vaccines to address a broad spectrum of neurodegenerative indications (Alzheimer’s disease, Parkinson’s disease, Down syndrome) and glaucoma as well. The Company’s pipeline features seven therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Abeta antibody that is licensed to Genentech entering phase III. AC Immune has also partnered three programs targeting Tau: ACI-35 with Janssen (therapeutic vaccine, phase Ib), Tau PET tracers with Piramal (Alzheimer’s diagnostic agent) and Tau-antibodies with Genentech (preclinical). The anti-Abeta vaccine ACI-24 phase I/IIa trial is run in house.
Others: * On May 9, 2016, AC Immune announced that it raised CHF 42.7 million in a private financing in which it issued Series E preferred shares to certain institutions and existing shareholders.
Therapeutic area: Neurological diseases - CNS diseases
